Radiation Oncology Journal

  • 제36권4호
  • /
  • Pages.304-316
  • /
  • 2018
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Elective neck treatment in clinically node-negative paranasal sinus carcinomas: impact on treatment outcome

  • Lee, Won Hee (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Choi, Seo Hee (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Kim, Se-Heon (Department of Otorhinolaryngology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Choi, Eun Chang (Department of Otorhinolaryngology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Lee, Chang Geol (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Keum, Ki Chang (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • 투고 : 2018.09.10
  • 심사 : 2018.12.19
  • 발행 : 2018.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The indication of elective neck treatment (ENT) for clinically N0 (cN0) paranasal sinus (PNS) carcinoma remains unclear. We aimed to investigate different treatment outcomes regarding ENT and propose optimal recommendations for ENT. Materials and Methods: We identified patients with cN0 PNS carcinoma who underwent curative-intent treatment between 1992 and 2015. Survival outcomes and pattern of failure were compared between patients who received ENT and those who did not. We sought to identify significant patient or pathologic factors regarding treatment outcomes. Results: Among 124 patients meeting the inclusion criteria, 40 (32%) received ENT ('ENT (+) group') and 84 (68%) did not ('ENT (-) group'). With a median follow-up of 54 months, the 5-year overall survival (OS) was 67%, and the 5-year progression-free survival (PFS) was 45%. There was no significant difference between the ENT (+) and ENT (-) groups regarding OS (p = 0.67) and PFS (p = 0.50). Neither group showed a significantly different pattern of failure, including regional failure (p = 0.91). There was no specific benefit, even in the subgroups analysis by tumor site, histologic type, and T stage. Nevertheless, patients who ever had regional and/or distant failure showed significantly worse prognosis. Conclusion: ENT did not significantly affect the survival outcome or pattern of failure in patients with cN0 PNS carcinomas, showing that ENT should not be generalized in this group. However, further discussion on the optimal strategy for ENT should continue because of the non-negligible regional failure rates and significantly worse prognosis after regional failure events.

키워드

참고문헌

  1. Silverberg E, Grant RN. Cancer statistics, 1970. CA Cancer J Clin 1970;20:11-23.
  2. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012;34:877-85.
  3. Paulino AC, Marks JE, Bricker P, Melian E, Reddy SP, Emami B. Results of treatment of patients with maxillary sinus carcinoma. Cancer 1998;83:457-65.
  4. Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys 2000;48:27-35.
  5. Kang JH, Cho SH, Kim JP, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg 2012;70:1717-23.
  6. Cantu G, Bimbi G, Miceli R, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Arch Otolaryngol Head Neck Surg 2008;134:170-7.
  7. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck 2002;24:821-9.
  8. Homma A, Hayashi R, Matsuura K, et al. Lymph node metastasis in t4 maxillary sinus squamous cell carcinoma: incidence and treatment outcome. Ann Surg Oncol 2014;21:1706-10.
  9. Pezner RD, Moss WT, Tong D, Blasko JC, Griffin TW. Cervical lymph node metastases in patients with squamous cell carcinoma of the maxillary antrum: the role of elective irradiation of the clinically negative neck. Int J Radiat Oncol Biol Phys 1979;5:1977-80.
  10. Kim GE, Chung EJ, Lim JJ, et al. Clinical significance of neck node metastasis in squamous cell carcinoma of the maxillary antrum. Am J Otolaryngol 1999;20:383-90.
  11. Le QT, Fu KK, Kaplan MJ, Terris DJ, Fee WE, Goffinet DR. Lymph node metastasis in maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys 2000;46:541-9.
  12. Jiang GL, Ang KK, Peters LJ, Wendt CD, Oswald MJ, Goepfert H. Maxillary sinus carcinomas: natural history and results of postoperative radiotherapy. Radiother Oncol 1991;21:193-200.
  13. Joosten M, de Bree R, Van Cann EM. Management of the clinically node negative neck in squamous cell carcinoma of the maxilla. Oral Oncol 2017;66:87-92.
  14. Gregoire V, Ang K, Budach W, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 2014;110:172-81.
  15. Park JH, Nam W, Kim HJ, Cha IH. Is elective neck dissection needed in squamous cell carcinoma of maxilla? J Korean Assoc Oral Maxillofac Surg 2017;43:166-70.
  16. Jeon SH, Han DH, Won TB, Keam B, Kim JH, Wu HG. Implication of tumor location for lymph node metastasis in maxillary sinus carcinoma: indications for elective neck treatment. J Oral Maxillofac Surg 2017;75:858-66.
  17. Paulino AC, Fisher SG, Marks JE. Is prophylactic neck irradiation indicated in patients with squamous cell carcinoma of the maxillary sinus? Int J Radiat Oncol Biol Phys 1997;39:283-9.
  18. Yang Z, Deng R, Sun G, Huang X, Tang E. Cervical metastases from squamous cell carcinoma of hard palate and maxillary alveolus: a retrospective study of 10 years. Head Neck 2014;36:969-75.
  19. Jang NY, Wu HG, Park CI, et al. Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. Jpn J Clin Oncol 2010;40:542-8.
  20. Kuo P, Manes RP, Schwam ZG, Judson BL. Survival outcomes for combined modality therapy for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg 2017;156:132-6.
  21. Takes RP, Ferlito A, Silver CE et al. The controversy in the management of the N0 neck for squamous cell carcinoma of the maxillary sinus. Eur Arch Otorhinolaryngol 2014;271:899-904.

피인용 문헌

  1. The Role of Elective Neck Treatment in the Management of Sinonasal Carcinomas: A Systematic Review of the Literature and a Meta-Analysis vol.13, pp.8, 2021, https://doi.org/10.3390/cancers13081842
  2. Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence vol.13, pp.11, 2018, https://doi.org/10.3390/cancers13112835